Log In
Print
BCIQ
Print
Print this Print this
 

surotomycin (CB-315) (formerly CB-183,315)

  Manage Alerts
Collapse Summary General Information
Company Cubist Pharmaceuticals Inc.
DescriptionOral antibacterial lipopeptide
Molecular Target
Mechanism of Action 
Latest Stage of DevelopmentPhase III
IndicationDiarrhea (infectious)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today